Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
18 Years
N/A
Both
Colonic Neoplasms
Trial Information
Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
In recognition of the fact that novel potential biomarkers are continually being identified
and will need to be validated in a rapid, efficient and scientifically rigorous manner, the
NCI has made an enormous commitment to the development of a network that will facilitate
biomarker development and validation in multiple organ sites. As part of the National Cancer
Institute-funded Early Detection Research Network (EDRN), the Great Lakes-New England
Clinical Epidemiological Center (GLNE CEC) proposes a research study that validates
potential molecular markers ("biomarkers") for the detection of precancerous and cancerous
conditions and cancer risk assessment. Although examples of such biomarkers are currently
in clinical use (i.e. CEA, CA-125), there are limitations to all of them. Our consortium
focuses on gastrointestinal neoplasia. The goals of this phase of the proposed research are:
1. Assessment of the utility of individual stool-based, serum-based and urine-based
biomarkers for discriminating between patients with adenocarcinomas, patients with
adenomas, patients without adenomas and normal subjects.
2. Assessment of the utility of individual stool-based, serum-based and urine-based
biomarkers for detecting indicators of carcinogenesis known to be present or not
present in adenomas, adenocarcinomas, and normal mucosa.
3. Construction of a panel of markers from those considered in Objectives 1 and 2 to
discriminate, under a number of assumptions concerning prevalence and cost of
misclassification, between:
a Subjects with normal colons versus patients without adenomas, patients with adenomas
and patients with cancers; b Subjects with normal colons, patients without adenomas and
patients with adenomas, versus subjects with cancers; c Subjects with normal colons
versus patients without and patients with adenomas versus patients with cancers.
4. Comparison of the characteristics of individual markers and panels as discriminators to
those of the established current standard, Fecal Occult Blood test (FOBT).
5. Development of a bank of stool samples linked to serum, tissue, urine and clinical data
from patients with colorectal cancer, adenomas and normal controls for validation of
stool-based markers that may be developed in the future.
To meet our goals the investigators propose to collect stool, rectal mucus, serum, plasma,
and urine samples from 800 subjects (200 colorectal cancers, 200 adenomas, 200 higher risk
normals and 200 normal colons for controls). The stool samples will be assayed for
stool-based biomarkers. EDRN Common Data Elements (CDEs) will be completed by the
recruiting sites and provided for the laboratories developing the assay.
Inclusion Criteria:
- Willing to sign informed consent
- Able to physically tolerate removal of up to 58 ml of blood at one to two different
time points
- Adults at least 18 years old
- Willing to collect 1-2 stool samples and prepare a FOBT card and five specimen vials
from each stool sample
- Pregnant or nursing women who otherwise meet the eligibility criteria may participate
- Subjects with one of the following:
- Colorectal adenocarcinoma—not treated and in colon at time of stool collection (CRC
bin)
- Adenoma-pathologically confirmed adenoma present in colon at time of stool collection
(Adenoma Bin)
- Higher Risk Normal Bin Subjects with a personal history of adenomas (confirmed by
pathology) with none present on qualifying colonoscopy Subjects with a personal
history of CRC (longer than 3 years ago because of exclusion criteria of cancer
within last 3 years) with none present at time of qualifying colonoscopy Any family
history of CRC (1st degree relative)
- Normal Control Bin
- No history or current finding of any colon neoplasia including CRC, adenomas, no
personal or family history of HNPCC or FAP
- Subjects who had CRC that was successfully treated at least three years ago may be
considered eligible for the adenoma bin if their polyps are adenomas and there is no
evidence of CRC or for the higher risk normal bin as noted above.
- Subjects whose screening colonoscopy shows any of these types of polyps may be
included in the normal or the higher risk normal bin if they meet the other criteria
noted above.
- Hyperplastic polyps
- Benign mucosal polyps
- Polypoid granulation tissue
- Prolapsed mucosal polyps
- Inflammatory polyp
- Transitional mucosal polyp
- Lipoma
- Gangleoneuroma
- Neuroma
- Hamartomatous polyp
Exclusion Criteria:
- Cancer patients who have had any surgery, radiation, or chemotherapy for their
current colorectal cancer prior to collecting the baseline samples
- Patients with a history of or clinically active Inflammatory Bowel Disease
- Patients with known HNPCC or FAP
- Inability to provide informed consent.
- Other active malignancy within 3 years of enrollment except any of the following:
- Squamous cell carcinoma of the skin
- Basal cell carcinoma of the skin
- Carcinoma in situ of the cervix, Stages Ia or Ib invasive squamous cell
carcinoma of the cervix treated by surgery only. (Excluded if had pelvic
radiation)
- Stage Ia Grade 1 adenocarcinoma of the endometrium treated with surgery
- Subjects with known HIV or chronic viral hepatitis
Type of Study:
Observational
Study Design:
Observational Model: Case Control, Time Perspective: Cross-Sectional
Principal Investigator
Dean E Brenner, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Michigan
Authority:
United States: Institutional Review Board
Study ID:
GLNE 007
NCT ID:
NCT00843375
Start Date:
December 2005
Completion Date:
April 2010
Related Keywords:
- Colonic Neoplasms
- Adenoma
- Neoplasms
- Colonic Neoplasms
- Colorectal Neoplasms
Name | Location |
|---|---|
| University of Michigan | Ann Arbor, Michigan 48109-0624 |
| Dana Farber Cancer Institute | Boston, Massachusetts 02115 |
| M.D. Anderson Cancer Center | Houston, Texas 77030 |
